How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
HR+HER2- Breast Cancer Market
- By Line of Therapy: First-line treatment, Second-line treatment, Third-line and beyond
- By Treatment Modality: Endocrine therapy, Chemotherapy, Targeted therapy, Immunotherapy
- By Patient Menopausal Status: Premenopausal, Postmenopausal
- By Disease Stage: Early-stage HR+HER2- breast cancer, Locally advanced HR+HER2- breast cancer, Metastatic HR+HER2- breast cancer
- By Biomarker Profile: PIK3CA-mutated, ESR1-mutated, Wild-type for PIK3CA and ESR1
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - First-line treatment leads By Line of Therapy at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 282 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.170 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the HR+HER2- Breast Cancer Market report
A complete, evidence-based study - 12 chapters and 118 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Line of Therapy 3
Treatment Modality 4
Patient Menopausal Status 2
Disease Stage 3
Biomarker Profile 3
Companies profiled
Roche
Novartis
Pfizer
AstraZeneca
Eli Lilly and Company
Daiichi Sankyo
Seagen Inc.
GlaxoSmithKline
Sanofi
Amgen
Bristol-Myers Squibb
Merck & Co.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Roche
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Novartis
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Pfizer
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →AstraZeneca
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Eli Lilly and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Daiichi Sankyo
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Seagen Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →GlaxoSmithKline
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Sanofi
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Amgen
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Bristol-Myers Squibb
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Merck & Co.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Johnson & Johnson
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Takeda Pharmaceutical Company
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Bayer
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,128M by 2033 · 7.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- First-line treatment48.4
- Second-line treatment20.5
- Third-line and beyond31.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$564.6M → $1,138M · 9.2%
Europe$393.5M → $800.8M · 9.3%
Asia Pacific$359.3M → $643.0M · 7.5%
Latin America$222.4M → $388.4M · 7.2%
Middle East and Africa$171.1M → $287.3M · 6.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.792026
7.792027
7.812028
7.812029
7.832030
7.852031
7.862032
7.872033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Roche12.4
- Novartis17.0
- Pfizer7.5
- AstraZeneca12.2
- Eli Lilly and Company11.2
- Daiichi Sankyo11.7
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Line of Therapy22.9%
Treatment Modality36.3%
Patient Menopausal Status16.1%
Disease Stage12.4%
Biomarker Profile12.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.9
- Europe24.6
- Asia Pacific19.7
- Latin America11.9
- Middle East and Africa8.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Roche | 86 | 85 | 76 | 91 | 94 | 94 | 88 |
| Novartis | 74 | 80 | 74 | 83 | 69 | 84 | 77 |
| Pfizer | 81 | 70 | 69 | 81 | 70 | 73 | 74 |
| AstraZeneca | 58 | 68 | 63 | 70 | 75 | 69 | 67 |
| Eli Lilly and Company | 56 | 64 | 72 | 74 | 59 | 54 | 63 |
| Daiichi Sankyo | 46 | 50 | 48 | 63 | 54 | 53 | 52 |
| Seagen Inc. | 59 | 66 | 45 | 60 | 45 | 42 | 53 |
| GlaxoSmithKline | 41 | 55 | 50 | 58 | 47 | 38 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Roche
- Novartis
- Pfizer
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Roche | ✓ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Novartis | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Pfizer | ✓ | ◐ | ◐ | ✓ | ✓ | ◐ |
| AstraZeneca | ◐ | ✓ | − | ◐ | ✓ | ✓ |
| Eli Lilly and Company | − | ◐ | ◐ | ◐ | − | ◐ |
| Daiichi Sankyo | − | − | − | ◐ | − | − |
| Seagen Inc. | ◐ | − | − | ◐ | ◐ | − |
| GlaxoSmithKline | ◐ | − | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Roche88
2Novartis77
3Pfizer74
4AstraZeneca67
5Eli Lilly and Company63
6Seagen Inc.53
7Daiichi Sankyo52
8GlaxoSmithKline48
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Roche
Challenger3
Strong scale, closing on the leaders.
NovartisPfizerAstraZeneca
Contender1
Focused players with pockets of strength.
Eli Lilly and Company
Niche3
Specialists in a single segment or region.
Daiichi SankyoSeagen Inc.GlaxoSmithKline
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Line of Therapy in North America, then scale across HR+HER2- Breast Cancer Market — a $265M beachhead inside a $4.18B market.
Beachhead (SOM)$265Mobtainable near-term
Serviceable (SAM)$1.67Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
First-line treatment
Best fit — highest urgency & budget in Line of Therapy.
Economic buyer77 fit
Second-line treatment
Strong fit — clear ROI and a fast path to value.
End user70 fit
Third-line and beyond
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Line of Therapy in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Modality & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Patient Menopausal Status
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel27%
Digital / self-serve23%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Line of Therapy leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win HR+HER2- Breast Cancer Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified21%
Evaluation12%
Closed-won7%
$14.6KCAC
$68KLTV
4.7:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
HR+HER2- Breast Cancer Market is a high-growth opportunity — $4.86B by 2033, compounding at 10.4%.
TAM · 2025$2.21Btoday
TAM · 2033$4.86Bforecast
CAGR10.4%2027–2033
Cumulative$30.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.86BTotal addressable market
SAM$2.02BServiceable available market
SOM$323MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.4% CAGR
Demand compounds through 2033, outpacing GDP across Line of Therapy.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Line of Therapy moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.86BLarge & growingTAM by 2033 at 10.4% CAGR
$2.02BServiceable nowreachable with today’s model
$323MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.79BBear6.7% CAGR
$4.86BBase10.4% CAGR
$6.22BBull13.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Modality optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
HR+HER2- Breast Cancer Market — a $1.38B market by 2033. Plan: grow share from 10.8% to 18.1%.
Market size · 2033$1.38Btotal addressable
Market CAGR4.2%2027–2033
Target share18.1%from 10.8% today
Revenue ambition$250Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.8% | 18.1% | Behind |
| Revenue | $156M | $250M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 30.9% | 41.9% | Behind |
| Customer retention | 87.6% | 95.1% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Line of Therapy
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Modality capability
A defensible second engine — invest in Treatment Modality to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Line of Therapy share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Modality
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $37M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Modality
- Authorise North America expansion plan
- Fund R&D program for Line of Therapy leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the HR+HER2- Breast Cancer Market conversation — a $5.26B market you can size, segment and defend in minutes.
Market size · 2033$5.26Btotal opportunity
Growth3.3%CAGR to 2033
Addressable buyers945+accounts in scope
Typical ROI4.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Line of Therapy
Goal Grow share in Line of Therapy
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.9×return on cost, year one
< 4 mopayback period
$51K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
RocheNovartisPfizerAstraZenecaEli Lilly and CompanyDaiichi SankyoSeagen Inc.GlaxoSmithKline+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your HR+HER2- Breast Cancer Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
HR+HER2- Breast Cancer Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →H. pylori Test Kit Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportH-Pylori Noninvasive Diagnostic Tests Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportH. pylori Breath Test Kit Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportHPV Test Reagent kit Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportHPV Test Kit Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportHPV Test Kit (Fluorescence PCR Method) Market
Market size, share, segmentation and regional forecast.
$450M market · 2025 base year
View reportHPV Testing and Pap Test Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportHPV Testing and Pap Smear Testing Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportHPV Screening Test and Pap Test Market
Market size, share, segmentation and regional forecast.
$354M market · 2025 base year
View reportHPV Quadrivalent Vaccine Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportHPV Nucleic Acid Detection Products Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportHPV Molecular Detection Kits Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.